Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Merck
Johnson and Johnson
Harvard Business School
US Department of Justice
Covington
Julphar
Baxter
Federal Trade Commission
Deloitte

Generated: April 19, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,683,037

« Back to Dashboard

Which drugs does patent 7,683,037 protect, and when does it expire?

Patent 7,683,037 protects LEXISCAN and is included in one NDA.

This patent has twelve patent family members in twelve countries.
Summary for Patent: 7,683,037
Title:Myocardial perfusion imaging method
Abstract:The present invention relates to methods for myocardial imaging by administering at least one 2-adenosine N-pyrazole, 2-adenosine C-pyrazole or a combination thereof A.sub.2A adenosine receptor agonist to a human undergoing myocardial imaging. The invention also relates to methods of producing coronary vasodilation without significant peripheral vasodilation by administering at least one 2-adenosine N-pyrazole, 2-adenosine C-pyrazole or a combination thereof adenosine A.sub.2A adenosine receptor agonist to a human.
Inventor(s): Belardinelli; Luiz (Menlo Park, CA)
Assignee: Gilead Palo Alto, Inc. (Foster City, CA)
Application Number:10/629,368
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 7,683,037

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Astellas LEXISCAN regadenoson SOLUTION;INTRAVENOUS 022161-001 Apr 10, 2008 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial METHOD FOR STIMULATING CORONARY VASODILATION FOR PURPOSES OF IMAGING THE HEART ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 7,683,037

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,470,801 Myocardial perfusion imaging methods and compositions ➤ Try a Free Trial
8,906,878 Myocardial perfusion imaging methods and compositions ➤ Try a Free Trial
9,289,446 Myocardial perfusion imaging methods and compositions ➤ Try a Free Trial
8,133,879 Myocardial perfusion imaging methods and compositions ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 7,683,037

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2003259264 ➤ Try a Free Trial
Canada 2492855 ➤ Try a Free Trial
China 1671399 ➤ Try a Free Trial
European Patent Office 1524984 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Julphar
Moodys
Citi
Deloitte
Cantor Fitzgerald
Healthtrust
Accenture
Covington
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.